A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease
- Conditions
- Parkinson Disease 3Parkinson-Dementia SyndromeParkinson DiseaseParkinsons Disease With DementiaParkinson Disease 2Parkinson Disease 4
- Interventions
- Other: No Intervention
- Registration Number
- NCT04148326
- Lead Sponsor
- ProgenaBiome
- Brief Summary
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Parkinson's Disease.
- Detailed Description
The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records regarding Parkinson's Disease.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
- Male or female patients of any age (interest is given to children to compare with mothers).
- Diagnosis of Parkinson's Disease
- Refusal to sign informed consent form
- History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
- Postoperative stoma, ostomy, or ileoanal pouch
- Participation in any experimental drug protocol within the past 12 weeks
- Treatment with total parenteral nutrition
- Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial
- Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients No Intervention Patients who have been diagnosed with Parkinson's Disease
- Primary Outcome Measures
Name Time Method Correlation of Microbiome to Parkinson's Disease via Relative Abundance Found in Microbiome Sequencing One Year Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized among specific disease types
- Secondary Outcome Measures
Name Time Method Validation of Sequencing Methods One year To validate the methods used to sequence samples
Trial Locations
- Locations (1)
ProgenaBiome
🇺🇸Ventura, California, United States